Podcasts about rpv

Tune into this podcast to revisit discussions led by global experts, Karine Lacombe, MD, PhD, and Chloe Orkin, MBChB, FRCP, MD, featuring the latest updates on HIV treatment and prevention from the 2025 IDWeek and EACS conferences.Topics covered include:Real-world safety and efficacy of long-acting ARTART switch: preferences, treatment satisfaction, changes in weight and metabolic parameters, and HBV reactivation riskInvestigational therapiesUpdates on long-acting PrEP: persistence, use in people with substance use disorder, and coadministration with gender-affirming hormone therapyHIV and STI screening with PrEPSTI prevention To download the accompanying slides, visit the program page for this episode:https://bit.ly/3MGvegMPresenters:Karine Lacombe, MD, PhDProfessor of MedicineSorbonne UniversityHead of Infectious Diseases UnitSt Antoine Hospital, AP-HPParis, FranceChloe Orkin, MBChB, FRCP, MDProfessor of Infection and InequitiesDean for Healthcare TransformationQueen Mary University of LondonFaculty of Medicine and DentistryHonorary Consultant PhysicianBarts Health NHS TrustLondon, United KingdomGet access to all of our new episodes by subscribing to the Decera Clinical Education Infectious Diseases Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Fear of virologic failure is a major barrier to ensuring that people living with virally suppressed HIV are receiving the most optimal antiretroviral therapy (ART) regimen for them. Stream this Medical Minute to learn more about key guideline recommendations regarding ART switch and reassuring clinical data regarding efficacy, tolerability, and quality of life associated with switching a suppressive ART regimen. Topics covered include:Efficacy of switching to 2-drug oral ART: real-world evidenceReal-world analyses of virologic failure with switch to long-acting cabotegravir plus rilpivirinePatient selection to reduce risk of virologic failure with switch Regimen-specific switch considerationsPresenters:Dima Dandachi, MD, MPH, FIDSA, FACPAssociate Professor of MedicineDivision of Infectious DiseasesUniversity of MissouriMedical DirectorHIV Treatment and Prevention Program, MUHCMedical DirectorBoone County Public Health and Human ServicesColumbia, MissouriChloe Orkin, MBChB, FRCP, MDProfessor of Infection and InequitiesDean for Healthcare TransformationQueen Mary University of LondonFaculty of Medicine and DentistryHonorary Consultant PhysicianBarts Health NHS TrustLondon, United KingdomLink to full program and accompanying slides:https://bit.ly/3KPN0xbGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

All Home Care Matters and our host, Lance A. Slatton were honored to welcome Pam Cusick as guest to the show.   About Pam Cusick, Senior Vice President at Rare Patient Voice:   Pam Cusick is an experienced research professional with more than 30 years of expertise in study design, implementation, and analysis. Her background in public health communications and research, coupled with her passion for patient advocacy, dovetail with Rare Patient Voice's mission and vision. She hopes to expand Rare Patient Voice's panels to include all patients and caregivers who want to share their opinions and impact their disease category.   Pam earned a BA in Psychology from Sweet Briar College, and a MA in Psychology from the New School for Social Research. She is Past-President of the Board of Directors and Scientific Advisory Council Lead for the Horses and Humans Research Foundation. In addition, Pam has recently been named a Laureate by the Insights Association! This recognition, given by peers across the industry, is a true lifetime honor—and she is "still taking it all in."   As Senior Vice President, Pam's focus is on the continued growth and success of RPV, with an eye on client services, business development, and oversight of patient outreach, panel management, and marketing.   About Rare Patient Voice:   Rare Patient Voice, LLC connects patients and family caregivers of rare and non-rare diseases with opportunities to share their opinions with companies and researchers by participating in all types of research studies. These include surveys and phone interviews, online bulletin boards, focus groups, clinical trials, and more.   While RPV began with a focus on rare diseases, we now welcome patients and family caregivers living with all medical conditions. We currently cover more than 1,500 rare and non-rare diseases and conditions. Over the years, we have paid patients and family caregivers over $15 million for participating in research.   We work with thousands of organizations, patient advocacy groups, and individuals to spread the word about RPV. Since launching in the United States in 2013, RPV has expanded across the globe. We now recruit patients and caregivers for research studies in the United States, United Kingdom, Canada, Germany, Italy, France, Spain, Australia, and New Zealand.    

Send us a textCRO veteran Dylan Ander (Founder, heatmap.com) joins Jordan to spill the never-before-shared story of how he landed heatmap.com by acquiring an entire C-Corp—and why the name matters for brand authority, SEO, and inbound. We break down why GA4 falls short for eCommerce, how definitions (sessions, idle windows, engagement) skew your numbers vs Shopify, and what to use when you need buyer-truth, not vanity metrics.Dylan unveils element-level revenue analytics—Revenue per Click (RPC) and Revenue per Session (RPS)—plus the coming Revenue per View (RPV), so you can prioritize changes that actually increase cash, not just clicks. We dig into pixel-level behavior tracking (no cookies, no PII), AI insights that call out underperforming elements (e.g., a specific FAQ item), and how to catch bugs and bot traffic before they burn revenue.We also get tactical on replacing Google Optimize, the realities of SaaS pricing (and why “McDonald's pricing” works), and the rise of social search (TikTok as a top search engine) shaping product discovery more than LLM/Chat. If you own a P&L for a DTC brand—or you're the CRO/performance lead—this episode will make you money.What you'll learn→ How Dylan cold-outreaches to acquire companies & premium domains (the “urgent, must speak to founder” play)→ Why GA4 under-/over-reports vs Shopify—and how definitions (idle windows, engagement) distort truth→ The RPC/RPS (and coming RPV) metrics that finally connect elements → revenue→ Pixel-level behavior tracking (no cookies/PII) + AI insights that tell you exactly what to change→ Social search optimization (TikTok search often beats LLM/Chat for product discovery)→ Replacing Google Optimize and building reliable A/B workflows in 2025→ The real cost drivers behind SaaS pricing—and how to price without burning trust→ Bot/junk filtering and defining a “session” that reflects buyers, not noiseWho this is for→ DTC/eCommerce founders & growth leaders→ CROs, performance marketers, and Shopify teams→ SaaS operators curious about pricing, PLG, and analytics positioningTimestamp:00:00 Intro & why this convo matters for DTC02:00 The C-Corp acquisition story behind heatmap.com06:30 Exact-match domains, SEO, and the inbound engine09:20 GA4 vs Shopify: definitions that change your numbers16:30 RIP Google Optimize: reliable A/B testing in 202518:50 Element-level revenue: RPC, RPS (and RPV coming)22:30 Pixel-level tracking & AI insights (no cookies/PII)26:15 Catching bugs + filtering bots/junk traffic28:40 Social search: TikTok as a top product discovery engine31:20 SaaS pricing & the “McDonald's” strategy36:40 Who should use revenue-based heatmaps (and why)44:30 Contrarian analytics takes you need to hear55:10 Personal: life, music, and loving the gameGuestDylan Ander — Founder, heatmap.com (revenue-based heatmaps, funnels, analytics for ecom). Mentions his upcoming book, Billion Dollar Websites.

Hear from experts in HIV care Beatriz Grinsztejn, MD, PhD, and Rosie Mnggibisa, MBChB, MPH, as they discuss their insights on some of the most clinically relevant new data presented at IAS 2025, including studies on: Gaps in care for adolescents and young adults living with HIVGlobal impact of funding cutsAntiretroviral therapy for treating HIVPatient management strategies for people living with HIV and obesityPresenters:Beatriz Grinsztejn, MD, PhDDirectorSTI/HIV Clinical Research LaboratoryEvandro Chagas National Institute of Infectious Diseases – FIOCRUZRio de Janeiro, BrazilRosie Mngqibisa, MBChB, MPHClinical DirectorPrincipal InvestigatorEnhancing Care FoundationDurban, South AfricaLink to full program: https://bit.ly/4otF8AR

Que capacitar pessoas é importante, todo - ou quase todo - gestor, líder e RH sabe muito bem. Que hoje há mais ferramentas e processos que tornam o treinamento e desenvolvimento mais completo e inovador, também. Contudo, será que todo esse potencial é colocado em prática? Se sim, a capacitação vem sendo realizado com uma estratégia bem definida ou ainda muito "fazer por fazer"?Co-founder e CEO da Alura, e colunista RPV, Adriano Almeida, é quem traz luz à importância de um treinamento protagonista, com as dicas para o seu negócio se destacar nesta importante frente de competitividade. Confira o papo.Não deixe de acompanhar o RH Pra Você Cast nos principais tocadores e em nosso canal no YouTube. https://linklist.bio/RHPraVcCast Aproveite para seguir e interagir em nossas redes sociais: Facebook: https://www.facebook.com/RhpraVoce Instagram: https://instagram.com/rhpravc LinkedIn: https://www.linkedin.com/company/rhpravc/

Soil testing in the Eaton Area / News Whip: Homeowner vs. Land in RPV. Selena Gomez comes out with Horchata Oreos / #SelenaGomez #Oreos #RanchoPalsVerdes // Breakdown of Metro budget and all the safety concerns. PCH to reopen #PCH // Memorial Weekend travel. Today is the busiest travel day. Where are you going? #MemorialWeekend  Stu Mundel flies over the best beaches and what is named best state beach? Crystal Cove in Orange County. #CrystalCove #NewportBeach #OrangeCounty #Ocean // Seattle Space Needle getting a $100 million renovation #SpaceNeedle #Seattle First double decker elevator in North America. Skyliner is double deck elevator glass floor to ceiling #Skyliner  

Jetzt endlich haben wir den Käpt'n himself an Land gezogen. Genug von den Deckschrubbern, heute wird der Käpt'n befragt. Ob freiwillig oder mit Säbel an der Kehle, das erfahrt ihr nur hierDies und vieles mehr erfahrt ihr in dieser FolgeHeute mit : Fabian, Martin, Matthias und Werner KlockeKEYWORDSHoly, Holysquad, Freebooter Miniatures, Freebooters Fate, Games Workshop, Warhammer 40k, Warhammer Fantasy Battles, Warhammer the old World, Ascending Fate, Werner Klocke, Role Play Verse, RPV, Reaper, Franz Sander, Golden Demon, Terry Pratchett, 3D Sculptor, Modellieren, Sculptor, Miniaturenherstellung, Firmengründung, Taschengelddieb, Mini Wargaming, MWG, Cerxes,Wir sind der Podcast aus dem (Ruhr)Pott mit interessanten Themen und Gästen rund um das Thema TableTop, Brettspiele, Gesellschaftsspiele, Miniaturen, Geländebau, TableTop News.Weitere Informationen auf ⁠⁠⁠⁠⁠https://www.tablepott.de⁠⁠⁠⁠⁠  oder in unserem Linktree : ⁠⁠⁠⁠⁠https://linktr.ee/TablePott⁠⁠⁠⁠⁠------- Links -------Webseite ⁠⁠⁠⁠⁠http://www.tablepott.de ⁠⁠⁠⁠⁠Spenden ⁠⁠⁠⁠⁠https://www.paypal.com/paypalme/TablePottcast ⁠Mörtsch ⁠⁠⁠⁠⁠https://www.getshirts.de/tablepott ⁠⁠⁠⁠⁠ Linktree : ⁠⁠⁠⁠⁠https://linktr.ee/TablePott⁠⁠⁠⁠⁠------- Shownotes -------Partner: HOLY ⁠⁠⁠⁠⁠https://de.weareholy.com/⁠⁠⁠⁠⁠ Ab sofort habt ihr 5€ Rabatt mit dem Rabattcode TABLEPOTT5 oder 10% Rabatt auf eure Bestellung mit den Code TABLEPOTT.Freunde:Feldherr: ⁠⁠⁠⁠⁠https://www.feldherr.com/ ⁠⁠⁠⁠⁠------- Folgen-Shownotes ------https://www.freebooterminiatures.de/------- Disclaimer -------The following music was used for this media project:⁠⁠⁠⁠⁠https://linktr.ee/TablePott⁠⁠

The Mountain Fire in Ventura County grows to 20,000 acres as dangerous winds batter the region. Jill Replogle updates us on the asbestos clean-up as Tustin marks one year since the hangar fire. The clock is ticking on home buyouts in RPV. Plus, more. Support The L.A. Report by donating at LAist.com/join and by visiting https://laist.comSupport the show: https://laist.com

There's a new buyout programs for homeowners living in the Portuguese Bend neighborhood of RPV. UCLA baseball will get some access back to its stadium and practice field on the Veterans Affairs campus in West L.A. We continue our Spooky LA series with a trip to what some say is the most haunted building around: The Hotel Cecil. Plus more.  Support The L.A. Report by donating at LAist.com/join and by visiting https://laist.com  Support the show: https://laist.com

Michael Monks on the Menendez Brothers Presser // Steve Gregory recipient of Edward R. Murrow for LGBTQ+ Special // Report of plane crash Rancho Palos Verdes / Dodger Game 3 / Shohei Ohtani 50-50 ball going up for auction / WHIP: Elon Musk net worth $247 Billion / Cosm Event Venue // Dorito's After Dark / Possible plane crash in RPV 

Witness saw plane go down in RPV but no planes have been reported missing / Liam Payne, member of One Direction / More Deli meat listeria // Creepy people behind home plate at Dodgers game / Starbucks making changes – cutting discounts / Jojo Wright 1027 KIIS on the death of One Direction's Liam Payne // Was it a plane or a UFO over RPV? // Bad news for Monkeys in Hong Kong 

PROTECTING THE 2024 VOTE, & A WEBINAR ON NEW NUKES > > We start GREEP Zoom #193 with the great ANDREA MILLER, who lays out her powerful push for getting out the vote in key swing states, including Florida, Georgia and North Carolina. > > STEPHEN SPITZ explains his very mixed experience with young election workers at the University of Michigan. > > RAY MCCLENDON follows by describing the mixed impacts of manipulated polls and the stripping of voter registration rolls in Georgia and elsewhere. > > A major election outcome prediction made by Alan Lichtman, who has been right many times before, is analyzed by TATANKA BRICCA. > > > We then shift gears to our Nuclear Webinar, starting with Michigan-based reporter ROGER RAPOPORT, who gives us the low-down on the insane attempt to re-fire the Palisades atomic reactor. > > World-renowned health researcher JOE MANGANO confirms the death toll from TMI, Fermi, Palisades and other nukes linked to radiation emissions from these “perfectly safe” loser reactors. > KEVIN KAMPS of Beyond Nuclear adds Fermi I and other destroyed or decrepit nukes to the murderous list. We pay homage to the great Philadelphia Inquirer op ed against TMI from the great Jane Fonda.  LINDA SEELEY from the San Luis Obispo Mothers for Peace updates us on the latest developments from Diablo Canyon, and reminds us that badly embrittled pressure vessel at Unit One is identical to the RPV at Palisades.. SHERI MCWHIRTER asks about the rule-making petition being circulated by Roger Rapoport. MYLA RESON reminds us of the steam generator disaster at San Onofre that forced that plant's permanent closure. Cleveland's CONNIE KLINE reports on the continuing energy disaster in Ohio. Santa Monica's PAUL NEWMAN asks about Betty Yee, a candidate for California governor who stabbed the renewables industry while she was on the Coastal Commission. LYNN FEINERMAN wonders if the fossil/nuke industry is using the “anti-woke” reaction to obstruct the rise of renewable energy worldwide. STEVE CARUSO wonders about the “crazy-whack” attack against renewables despite their plummeting price tag. Next week we will meet on Indigenous People's Day, hopefully to celebrate the release of LEONARD PELTIER.

In this episode of P4A Let's Talk Rare, hosts Georgie and Owen Bryant from Partners For Access are joined by Wes Michael, founder and president of Rare Patient Voice LLC. Wes shares the organization's journey from its beginnings as a community project for hemophilia patients to a global platform that connects rare disease patients and caregivers with healthcare professionals. Rare Patient Voice has awarded over $30 million to participants and completed more than 210,000 projects, with Wes highlighting the company's organic growth through patient referrals and advocacy partnerships. Wes discusses the challenges of reaching patients nationwide, the rewarding impact of patient involvement in healthcare, and the essential role of patient-centricity in shaping drug development and health technology assessments. He emphasizes that patients' voices, as the end-users, are critical for creating effective healthcare solutions. Looking ahead, Wes shares his enthusiasm for expanding Rare Patient Voice into clinical trials and increasing its presence in Europe. The episode concludes with a call to action for patients and caregivers to join the Rare Patient Voice community and share personal stories to further understanding and awareness of rare diseases. Wes Michael Bio: A market research industry veteran of over 40 years, Wes earned his MBA from the University of Chicago Booth School of Business and a BA in English from the University of Pennsylvania. In 2013, Wes launched Rare Patient Voice, based on a novel approach to building a market research panel that enables patients and caregivers to share their voices with researchers and companies developing products to improve patients' lives. He structured the company on the core values of being a good patient resource, a good client partner, a good employer to staff, and a good citizen in our community. Since then, Wes has seen the company grow, expanding from the US to Canada, the United Kingdom, Spain, Italy, France, and Germany, completing thousands of projects, and providing customized service to hundreds of clients. He hopes that RPV's work can help the lives of patients and caregivers who have participated in our studies and those who come after. Episode Resources: Wes Michael on LinkedIn Rare Patient Voice LLC Website Owen Bryant on LinkedIn Georgina Rack on LinkedIn Partners4Access Website  P4A Let's Talk Rare podcast on Apple Podcasts

GUEST – Tim Lynn: Restricted flight zone for Trump over RPV when he comes to SoCal // Recapping the debate from last night. Debate betting was off the hook! // Keith Urban Album Release Party iHeartRadio Theatre giveaway // No one wants the Cherry Coke in the break room, except KiKi and Angel. 

Jill need your support ‼️ I wanted to share this with everyone and ask for your support. As you know I am very passionate about my health, and advocating for adrenal insufficiency. I was recently approached by RARE PATIENT VOICE. RPV brings the gap between patients and researchers. Patients have voice by being giving the opportunity to participate in research. RPV gives you, the patient the opportunity and you can choose if it is right for you. No obligation. No pressure. Your choice. Always. This can be as simple as a survey to clinical trials. It is all up to the individual and many opportunities you get paid up to $125 US/hour. Please join me. Register here:https://www.rarepatientvoice.com/rp/thepicklejar It is pretty amazing and open to anyone with a diagnosed illness. You simply register. Takes about 3 minutes. RPV reaches out if there is an opportunity. You decided if you choose to participate. If you want change. If you want progress. You need to register and give yourself to oppoutniry to have your voice heard. Again this is open to anyone with a diagsnosed illness. ADRENAL INSUFFICIENCY patients desaparetly needed. Only 366 registered in US. Only 18 registered in Candaa Only 44 registered in the UK. All patients deserve to have a voice. Please join me. Register here:https://www.rarepatientvoice.com/rp/thepicklejar Please share this information and link with anyone you know who has an illness/diagnosis and give them the oppotunity to be part of change. This is very important to me so I truly hope you considering join me. Jill ❤️

BE PART OF THE VOICE OF CHANGE: https://www.rarepatientvoice.com/rp/thepicklejar Do you have an illness and what to be a voice for change⁉️ Do you want to make a difference⁉️ ‼️JOIN ME and RARE PATIENT VOICE‼️ We need to be heard! A few weeks ago THE PICKLE JAR PODCAST was contacted by RARE PATIENT VOICE. They requested to have their VP PAM CUSICK on the podcast to share RARE PATIENT VOICE. RPV is our voice with illness. RPV advcoates between researchers and patients to improve care and treatment. ‼️THIS IS WHAT WE NEED.‼️ It is simple. REGISTER with RPV (link up above) RPV contacts you with opportunity to participate in research from surveys, trials etc. YOU have the CHOICE to say YES or NO Many opportunities you get paid for your involvement. RPV wants to increase their patients with adrenal insufficiency BUT anyone with any diagnosed illness can register. THIS IS A POSITIVE step for people with adrenal insufficiency. PLEASE register and give yourself the opportunity to be part of our voice for change. ‼️You want to be heard....now it is time.‼️ Registering is simple and takes less then 3 minutes. Please share this link and message to everyone you know with adrenal insufficiency or an illness who wants to be heard. The amazing podcast with Pam will be released soon JOIN ME...and be part of the voice of change. You know it will save lives! FOLLOW THIS LINK: https://www.rarepatientvoice.com/rp/thepicklejar

RPV city leaders learn the slide is deeper and faster-moving than originally thought. Also this evening: Artificial Intelligence will help monitor bike lanes in Santa Monica; and California takes a central role at the DNC.   

Tonix Pharmaceuticals CEO Seth Lederman speaks with with Proactive's Stephen Gunnion about the company's accelerated efforts to develop a single-dose vaccine for Mpox, TNX-801, in light of the World Health Organization's declaration of a global health emergency. Lederman highlighted the vaccine's promising results in animal studies, which showed protection against lethal challenges with Clade 1 Mpox virus and prevention of skin lesions, potentially blocking forward transmission. As the threat of more lethal strains like Clade 1 emerges, Tonix is ramping up its development process, focusing on producing GMP material suitable for human trials. The vaccine, based on Tonix's RPV platform, is designed for rapid distribution and could play a critical role in managing the public health crisis. Lederman also discussed the potential risks associated with Clade 1's spread beyond Africa, stressing the need for quick and effective solutions. With a single dose, this vaccine could provide a durable defense against Mpox, akin to vaccines for smallpox. The company's efforts reflect the urgency of the situation and the importance of innovative solutions in pandemic preparedness. Visit Proactive's YouTube channel for more videos, and don't forget to give this video a like, subscribe to the channel, and enable notifications for future content. #TonixPharmaceuticals #MpoxVaccine #SethLederman #TNX801 #PublicHealth #WHO #Monkeypox #Biotech #Pharmaceuticals #PandemicPreparedness#ProactiveInvestors #InvestmentStrategy #ProactiveInvestors ##invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

A Primeira Seção do Superior Tribunal de Justiça decidiu não são devidos honorários de sucumbência em cumprimento de sentença não impugnado pela Fazenda Pública, mesmo que o crédito esteja submetido a pagamento por meio de requisição de pequeno valor. Essa decisão foi tomada em julgamento realizado sob o rito dos recursos repetitivos, cadastrada como Tema 1.190. Isso significa que ela vai servir de base para os demais tribunais do país, quando julgarem casos idênticos. O relator, ministro Herman Benjamin, propôs a modulação dos efeitos da decisão para que só sejam alcançados os cumprimentos de sentença iniciados após a publicação do acórdão do julgamento. Segundo o ministro, a jurisprudência anterior do STJ considerava que, nas hipóteses de pagamento da obrigação por meio de RPV, seria cabível a fixação de honorários nos cumprimentos de sentença contra o Estado, ainda que não impugnados. Contudo, ele afirmou que o tema merece uma nova análise diante do Código de Processo Civil de 2015. Herman Benjamin explicou que a regra é o pagamento de honorários no cumprimento de sentença e na execução, resistida ou não. No entanto, destacou que o parágrafo 7º do artigo 85 do CPC de 2015 traz uma exceção quando estabelece que não serão devidos honorários no cumprimento de sentença contra a Fazenda Pública que enseje a expedição de precatório, desde que não tenha sido impugnada. Na avaliação do ministro, essa regra também alcança o cumprimento de sentença com a expedição de RPV. Para ele, no cumprimento de sentença que impõe a obrigação de pagar quantia certa, os entes públicos não têm a opção de pagar voluntariamente.

In 2013, Wes founded Rare Patient Voice to provide patients and their caregivers with the opportunity to voice their opinions through surveys and interviews to improve medical products and services. As with any new business, the initial days were challenging. Wes knew that he wanted to be able to share this resource with all clients, so he purposely did not accept investments from clients or other related sources. He spent time traveling across the country and meeting patients and caregivers at events such as awareness days, fundraising walks, meetings, and conferences. Eventually, the business grew and Wes was able to add staff to support projects and attend events.Wes has been amazed at the great reception Rare Patient Voice has received from both patients and the market research industry. To date, over $13 million dollars have been awarded to RPV participants. Working to meet the needs of advertising agencies, market research firms, pharmaceutical companies and other clients has been a labor of love for this longtime marketing professional. In addition to the United States, Rare Patient Voice now recruits patients and caregivers for studies in Canada, the United Kingdom, Germany, France, Italy, Spain, Australia, and New Zealand.

In this episode, Jonathan Appelbaum, MD, FACP, AAHIVS, discusses the newest data supporting LA ART use in people with adherence challenges or viremia, including:The LATITUDE study, an open-label phase III study of LA CAB + RPV in people with a suboptimal response or nonadherence to oral ARTUpdates to the Ward 86 cohort, which showed 81% of patients with viral suppression on LA CAB + RPV at Week 48The CARES study, an open-label, noninferiority phase IIIb study of LA CAB + RPV in people with baseline resistance mutationsPresenter:Jonathan Appelbaum, MD, FACP, AAHIVSLaurie L. Dozier, Jr., MD Education Director and Professor of Internal MedicineChair, Department of Clinical SciencesFlorida State University College of MedicineMedical DirectorCare Point Health and WellnessTallahassee, FloridaLink to the full program:https://bit.ly/49x0W6DLink to the slideset: https://bit.ly/4bzZothTo get access to all of our new podcast episodes, subscribe to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts or Spotify.  

In this episode, Joseph J. Eron, Jr., MD, and Monica Gandhi, MD, MPH, discuss the key HIV studies from CROI 2024 that are influencing their clinical practice, including:New data surrounding long-acting ART, including:The CARES study of LA CAB + RPV in a Sub-Saharan African population using a public health approachThe IMPAACT 2017 MOCHA study evaluating switching to LA CAB + RPV in adolescents living with HIVThe ACTG A5359 LATITUDE study of LA CAB + RPV in people with adherence challenges to oral ARTUpdated data from San Francisco's Ward 86 Clinic using LA CAB + RPV in people without viral suppression at baselineCase series of LA CAB (± RPV) + LEN for select people living with HIV unable to take oral ART and unable to use LA CAB + RPV aloneData on comorbidities and coinfections, including:A REPRIEVE proteomic analysis to elucidate mechanistic pathways of statin effects on plaqueThe ACTG A5371 SLIM LIVER study of semaglutide for MASLD in people living with HIVThe impact of Doxy-PEP guideline implementation on STIs in men who have sex with men and transgender women in San FranciscoPotential novel treatment options on the horizon for people living with HIV, including:Phase II data on LEN + ISL dosed orally once weeklyEarly data on other oral weekly optionsData on bNAbs in combination or with other ART agentsPresenters:Joseph J. Eron, Jr., MDProfessor of Medicine, School of MedicineHerman and Louise Smith Distinguished ProfessorChief, Division of Infectious DiseasesDirector, Clinical Core, UNC Center for AIDS ResearchAdjunct Professor of EpidemiologyGillings School of Global Public HealthUniversity of North Carolina at Chapel HillChapel Hill, North CarolinaMonica Gandhi, MD, MPHProfessor of MedicineDivision of HIV, Infectious Diseases, and Global MedicineMedical Director, Ward 86 HIV ClinicUniversity of California, San FranciscoSan Francisco, CaliforniaContent based on an online CME program supported by independent educational grants from Gilead Sciences; Merck & Co., Inc.; and ViiV Healthcare.Link to full program: https://bit.ly/4awdWJMGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts or Spotify.

Investing in a website that is not optimized for conversions is like pouring water into a leaky bucket with a hole in it. You are likely spending thousands of dollars on your digital marketing efforts, all to have your website not properly optimized to convert that traffic into buyers. Acquiring traffic is becoming increasingly expensive and competitive every single day. With the increased cost of customer acquisition, it's crucial that your brand converts as many visitors into buyers as possible. That's where ThrillX comes in. We are a Canadian-based UX/UI Design and Conversion Rate Optimization agency helping eCommerce and B2B brands improve conversion rates without even touching your ads. We put you in a position to scale your marketing efforts so that when you receive more traffic, the revenue you generate is amplified. How do we do it? We have a unique data-driven and repeatable conversion optimization process that we use to increase your conversion rates and all your KPIs (AOV, RPV, etc) sustainably over time. Our process combines our expertise in human psychology and behavioral science with analytics tools such as heatmaps, scroll maps, user-testing, surveys, A/B testing, custom landing pages, and customer interviews to identify pain points and motivations. Every decision we make is based on real data and statistics, eliminating the guesswork and maximizing results. Here are some past client results: → Increased Influence Hunter's form inquiries by 385% → Increased Wild Man Drinking's e-commerce purchases by 97%, AOV by 13.5%, and delivered 5X ROI in just a few months → Increased apparel conversions for Optimal Sports Management by 115% → Increased Fiddler's Green CBD's product sales by 67% in just 1 month To schedule a free website audit and strategy session, use the link below: https://calendly.com/arshsanwarwala/30min

Pam Cusick is an esteemed research professional with over 30 years of experience in study design, implementation, and analysis. Pam's journey in public health communications and research has been driven by her unwavering passion for patient advocacy, a passion that seamlessly aligns with Rare Patient Voice's mission and vision.As the Senior Vice President of Rare Patient Voice, Pam spearheads initiatives aimed at expanding the organization's panels to encompass all patients and caregivers eager to share their insights and influence their disease categories. Her dedication to amplifying patient voices is evident in her focus on the continued growth and success of RPV.Enthusiastically, Pam engages with patients and caregivers at various conferences and events, where she educates them about Rare Patient Voice's mission. When individuals express uncertainty about the value of sharing their experiences, Pam passionately assures them of the significance of their unique perspectives. You'll learn how public health research informs Pam's advocacy, how patients are empowered by sharing their stories, and why DEI is thriving in healthcare advocacy.LEARN MORE:>>www.rarepatientvoice.comNSLS MEMBERS ONLY:>>Listen to the bonus episode to learn how our community benefits from us all sharing our stories and why clinical research benefits from more inclusivity of patients. (https://thens.ls/3TjhSXt)Mentioned in this episode:Get 20% Off at the NSLS ShopUse code MONDAYS for 20% your entire purchase at shop.nsls.orgNSLS Shop

This show is actually  the prequel to last weeks show ( episode 14 ) ‘ Optimize the  Regular Patient Visit'.  Last week we discussed the solutions / answers to RPV optimization. This week, we'll discuss  the reasons less successful doctors SAY they don't want to that.  (AKA : Handling the objections some doctors put up that minimized their own success :-)

We can all agree, the thing we do most often is the regular patient visit.  But, how do we optimize it for the patient and the practice? On this episode, we'll talk about how to make it a true WIN-WIN! When we optimize the RPV, not only do patients get great results, you'll have more fun in practice and  the practice grows. 

Providing Patients and Caregivers a Voice   ⁠Rare Patient Voice⁠ connects patients and caregivers with the opportunity to voice their opinions through surveys and interviews to improve medical products and services. ⁠For patients and family caregivers⁠ —they provide study opportunities to voice their opinions on medical products and services while getting paid for their time. ⁠Sign up here⁠. ⁠For patient advocacy groups⁠ —they partner with advocacy and support groups to increase donations. ⁠For market research firms⁠ —they handle patient recruitment and help find the respondents and patient panels needed for marketing research. ⁠For pharmaceutical and biotech companies⁠ —they provide the respondents and patient communities required to support business insight needs and all types of research studies. Pam Cusick, Rare Patient Voice's Senior Vice President, is an experienced research professional with more than 30 years of expertise in study design, implementation, and analysis. Her background in public health communications and research, coupled with her passion for patient advocacy, dovetail with Rare Patient Voice's mission and vision. She hopes to expand Rare Patient Voice's panels to include all patients and caregivers who want to share their opinions and impact their disease category.   Pam earned a BA in Psychology from Sweet Briar College and an MA in Psychology from the New School for Social Research. Pam is past president of the Board of Directors and Scientific Advisory Council Lead for the Horses and Humans Research Foundation. As Senior Vice President, her focus is on the continued growth and success of RPV, with an eye on client services, business development, and oversight of outreach and panel management, marketing, and human resources.   Learn more: Website: ⁠https://rarepatientvoice.com/⁠ FB: @RarePatientVoice Twitter: @rarepatientvoic IG: rarepatientvoice Email: ContactUs@RarePatientVoice.com   Link to Transcript: ⁠https://docs.google.com/document/d/1B8_llq6kLTdQp9c4AWMOaUKs6hnYfv20YFqNK7S_plg/edit?usp=sharing⁠ As an Amazon Associate, I earn commissions from qualifying purchases. For more information about True North Disability Planning you can find us here: Web: ⁠⁠⁠⁠⁠⁠⁠⁠https://truenorthdisabilityplanning.com/⁠⁠⁠⁠⁠⁠⁠⁠ Waypoints - ⁠⁠⁠⁠⁠⁠⁠⁠https://waypoints.substack.com/⁠⁠⁠⁠⁠⁠⁠⁠ Facebook: @TrueNorthDisabilityPlanning X (Twitter): @NeedsNavigator --- Send in a voice message: https://podcasters.spotify.com/pod/show/abcs-disability-planning/message Support this podcast: https://podcasters.spotify.com/pod/show/abcs-disability-planning/support

According to a BCG report, only 19% of VCs have some kind of scientific or technological competence. And that creates a translation problem between deep tech founders and investors.  To close that gap, Arkady Kulik and his cofounder, Tamaz Khunjua, built RPV, a venture fund that brings scientific expertise to the market and helps scientists become strong entrepreneurs. On this episode of The Boost VC Podcast, Arkady joins us to explain how the RPV team's extensive background in science and entrepreneurship serves deep tech startups. Arkady describes how starting a venture fund differs from founding other companies and shares his excitement around ‘being at the edge of science' as a frontier tech VC. Listen in for Arkady's unique take on what it means to be useful to others and learn how RPV is working to make talented scientists billionaires! Topics Covered The idea behind RPVHelp scientists become strong entrepreneurs‘Commercialization of science' How Arkady got into venture capitalMoved to US to be part of scientific exploration of humanityLack of funding in prototyping stage of deep tech startups Arkady's biggest accomplishment before age 20Launched first company at 18 without external investmentScaled to annual revenue of $5M in third year How starting a venture fund differs from starting other companiesMore competitive, thousands of similar funds raising moneyHarer to differentiate and properly tell story of niche What part of being a VC Arkady enjoys the mostBeing at edge of science and meeting interesting peopleFinding processes that make things work The secret skills Arkady is most proud ofDeveloped extreme level of disciplineExtremely organized in managing time and data How Arkady thinks about being useful to othersProvide with relevant information or connectionsPut smile on someone's face, make life better The most valuable thing RPV provides for deep tech startupsExternal proof point for science and technologyEntrepreneurial experience and change management Arkady's ‘deathbed test' to measure successNothing ‘could have but didn't achieve'Self-actualization (happy, complex person) Connect with Arkady Kulik RPV https://rpv.global/RPV on LinkedIn https://www.linkedin.com/company/rpvglobal/Arkady on LinkedIn https://www.linkedin.com/in/arkady-kulik/Arkady on X https://twitter.com/arkadykulik  Resources Starburst Aerospace https://starburst.aero/Cantos VC https://cantos.vc/Countdown https://countdown.capital/Fifty Years https://fiftyyears.com/Productivity Planner https://www.intelligentchange.com/products/productivity-plannerTerraforming Mars https://www.fryxgames.se/games/terraforming-mars/Breakfast with Pops: A Venture Capital Handbook by Adam Draper and William H. Draper III https://www.amazon.com/Breakfast-Pops-Venture-Capital-Handbook/dp/B0C1JHXTQF Connect with Boost VC Boost VC Website https://www.boost.vc/Boost VC on Facebook https://www.facebook.com/boostvc/Boost VC on X https://twitter.com/BoostVCBoost VC on Instagram https://www.instagram.com/boost_vc/ 

Welcome to our summer series. You probably noticed a change in the intro right? Lol. We believe summer should be full of fun, good vibes, and great tunes! Was Michael A founded Rare Patient Voice in 2013 to give patients and family caregivers with rare diseases, the opportunity to voice their opinions and research studies. This year the company celebrates its 10th anniversary. Rare Patient Voice has now conducted thousands of studies and rewarding patients and family caregivers with over $10 million dollars for their participation. Many have been recruited in person by West himself at patient events and through a robust referral program with patient advocacy and support groups. Rare Patient Voice now covers non-rare as well as rare diseases and conditions and has expanded from the United States to Canada, the United Kingdom, France, Germany, Italy, Spain, Australia, and New Zealand Before launching Rare Patient Voice, Wes worked for healthcare market research firm Cantar health. He previously was a brand manager in marketing research manager at McCormick, the spice Company, and General Mills, working on Wheaties, total and kix cereals. He has a BA from the University of Pennsylvania and an MBA from the University of Chicago. I like to think of Wes, regardless of all his many accolades, as just another good dude and rare patient advocate. He is helping the community through one research study at a time. You can find Wes and the RPV team through these social media platforms: Website: https://rarepatientvoice.com Facebook: https://rarepatientvoice.com Insta: https://www.instagram.com/rarepatientvoice Linkedin: https://www.linkedin.com/company/rare-patient-voice

Ron talks with Wes Michael who founded Rare Patient Voice (RPV), a company that enables patients and caregivers to share their voices with the researchers and companies developing products to improve patient's lives.  RPV provides patients and caregivers an opportunity to participate in all types of research, including market research, health economics outcomes, real world evidence, user experience, human factor studies and clinical trials. RPV has over 100,000 patients and caregivers across more than 700 diseases both rare and non-rare.   Sponsors:    Hero Soap Company-Use code RAP for 10% discount                    www.herosoapcompany.com                    Blue Sky CBD   Use the link below or Promo Code RON for a 20% discount                   https://www.bluesky-cbd.com/pages/_go_?ref=3251:615856&discount=ron                    Feel Good Knees Method                   https://f75bdd6-s9sk9vdkb93locvr9j.hop.clickbank.net   Links:         Rare Patient Voice                   https://rarepatientvoice.com/itsawrapwithrap                    contactus@rarepatientvoice.com                   https://itsawrapwithrap.com                   #HC Univrersal Network

Ron talks with Wes Michael who founded Rare Patient Voice (RPV), a company that enables patients and caregivers to share their voices with the researchers and companies developing products to improve patient's lives.  RPV provides patients and caregivers an opportunity to participate in all types of research, including market research, health economics outcomes, real world evidence, user experience, human factor studies and clinical trials. RPV has over 100,000 patients and caregivers across more than 700 diseases both rare and non-rare.   Sponsors:    Hero Soap Company-Use code RAP for 10% discount                    http://www.herosoapcompany.com                    Blue Sky CBD   Use the link below or Promo Code RON for a 20% discount                   https://www.bluesky-cbd.com/pages/_go_?ref=3251:615856&discount=ron                    Feel Good Knees Method                   https://f75bdd6-s9sk9vdkb93locvr9j.hop.clickbank.net/   Links:         Rare Patient Voice                   https://rarepatientvoice.com/itsawrapwithrap                   https://rarepatientvoice.com                   https://itsawrapwithrap.com                   #HC Univrersal Network

In this episode, Ian Frank, MD, discusses long-acting HIV treatment with cabotegravir plus rilpivirine for people with HIV, including:Efficacy data with every-8-week dosingReal-world use in people with viremia Initiation and continuation strategiesVirologic failure dataSafety information Presenter:Ian Frank, MDAssociate ChiefDivision of Infectious DiseasesProfessor of MedicineUniversity of PennsylvaniaPhiladelphia, PennsylvaniaTo download the slides: https://bit.ly/3HX1GGn To view the full online program: https://bit.ly/3ZjSFhg 

Brad Redding, Founder & CEO @ Elevar (Connect on LinkedIn and Twitter) shares 5 specific examples of onsite conversion optimization improvements and the underlying data behind them. Brad also shares how to calculate the data behind a UX issue we found that could make a customer an extra $50K/month. Plus you'll learn about Elevar's new public Benchmark that charts key metrics like conversion rate, RPV, and others by revenue band, vertical, and date range. -----We release new episodes every week that go deep into the world of tracking, analytics, and conversion optimization.-----Links Referenced:Elevar Index BenchmarkPlus Stores -- How to maintain tracking when upgrading to checkout extensibilityGA4 event tracking setup tipsTrue Classic TeesElevar Changelog-----And if you're new to Elevar, Elevar automates server-side conversion tracking for Shopify. Check us out!

In this episode, Jill Blumenthal, MD, MAS, and William R. Short, MD, MPH, AAHIVS, address key considerations when evaluating ART safety and tolerability in pregnant people, those trying to conceive, and transgender individuals, such as:Approaching patients trying to conceive on nonpreferred ART regimens (eg, 2-drug regimens like LA CAB and RPV)Optimizing the use of the Antiretroviral Pregnancy RegistryAddressing unique barriers to ARV adherence in transgender individuals with HIV (eg, drug formulation considerations for ARV medications and gender-affirming hormone therapy, sperm banking or egg harvesting, drug coverage considerations)Faculty: Jill Blumenthal, MD, MASAssociate Professor of MedicineInfectious Diseases and Global Public Health University of California, San DiegoSan Diego, CaliforniaWilliam R. Short, MD, MPH, AAHIVSAssociate Professor of MedicineDivision of Infectious Diseases Department of Medicine  Perelman School of Medicine at the University of Pennsylvania Philadelphia, PennsylvaniaLink to full program:http://bit.ly/3PM3nYeLink to downloadable slides: http://bit.ly/3WgYycz

Precatório: o instrumento para pagamento de débito do ente público. Quebre o preconceito e encare uma nova oportunidade! Neste novo episódio do Direito Fora de Pauta, talvez o mais longo de toda a série, falaremos do precatório judicial, aquela ordem judicial pra pagamento de débitos pelos entes públicos. ATENÇÃO! Você que já ouviu falar, mas não tem a mínima ideia de como funciona; Você que quer fugir desesperadamente desta espécie de pagamento! Você que tem precatório já constituído e aguarda a sua vez de receber! Você quer quer enxergar uma nova oportunidade e área nova pra aumentar seus ganhos mensais! ESSE EPISÓDIO É PRA VOCÊ! - O que é um precatório? - Como são organizados os pagamentos? - Como funciona a fila de pagamento? - Como funciona a fila preferencial? - Qual a diferença para a RPV? - Por que pode ser uma nova oportunidade de potencialização dos ganhos mensais? O episódio mais completo e mais detalhado sobre tema e que promete ramificações abordado sempre formato descontraído e descomplicado e repleto de humor pelos advogados, Fábio Carvalho, Caio Almeida e com a presença ilustre de uma das maiores autoridades no país sobre o tema, o tributarista Felipe Cunha! *Obs: opinião pessoal de Fábio Carvalho - “o melhor episódio de todos os tempos” Vem com a gente! Avalie, critique, curta, compartilhe e nos marque nas redes sociais! Apresentação, direção e roteiro: ⁣Advogados Fábio Carvalho e Caio Almeida. Convidado: Felipe Cunha. Sigam nossas redes sociais: Instagram, TikTok, Twitter, Canal do Youtube e Facebook: @direitoforadepauta . Email: direitoforadepauta@gmail.com NÃO PERCAM!

In this episode, Eric Florence, MD, PhD, discusses how clinics can prepare for the implementation of long-acting injectable antiretroviral therapy, including:Clinical infrastructureEnsuring adequate space and injection equipmentMaintaining drug supply and temperature requirementsStaffingEnsuring there are staff able to focus on the implementation of LA ART, including well-trained nurses to administer the injectionsImplementing a system for scheduling follow-up injections and providing patient remindersHaving knowledgeable staff available to answer patient questions on their LA ARTEric Florence, MD, PhDPhysicianInternal Medicine, Infectious Diseases & Tropical MedicineUniversity Hospital of AntwerpEdegem, Brussels, BelgiumSee the full program at: https://bit.ly/3CsSvdX

In this episode, Laurence Slama, MD, PhD, describes some of the ways that her clinic is attempting to make IM injections of long-acting antiretroviral therapy more sustainable long term. She explains the logistics of how she has allowed for patients to receive their long-acting cabotegravir and rilpivirine doses through community nurses after receiving the first 3 doses in a clinical setting. She also discusses some of the benefits and challenges of this kind of flexible system for patients and healthcare professionals. Laurence SlamaDoctorDepartment of Infectious DiseasesHôtel Dieu, APHPParis, FranceSee the full program at:https://bit.ly/3CsSvdX

In this episode, Stephane De Wit, MD, PhD, discusses the benefits of long-acting antiretroviral therapy (ART) for migrant populations in Europe—and specifically in Belgium. He also addresses some of the challenges of accessing and following up with those populations.Dr De Wit describes some of the ways that the Belgian healthcare system is set up to improve access to ART. He then explains some of the disease parameters for considering expanding the use of long-acting ART to patients who are not virologically suppressed. Finally, Dr De Wit offers some thoughts about the future of long-acting ART to migrant populations in Belgium.Stephane De Wit, MD, PhDFormer HeadInfectious DiseasesSaint Pierre University HospitalBrussels, BelgiumSee the full program at:https://bit.ly/3HIMAoF

In this episode, Annette Haberl, MD, and William R. Short, MD, MPH, AAHIVS, discuss when to consider an ART switch during pregnancy, including:Current DHHS, EACS, WHO, BHIVA, and German/Austrian guidelines for the use of ARVs in pregnancyWhat data and recommendations for the use of ARVs during pregnancy are currently missing from the guidelinesAvailable data on newer ARVs in the ARV pregnancy registryPharmacokinetic data for newer ARVs including BIC/FTC/TAF and LA CAB + RPV in pregnancyRecommendations for 2-drug ART regimens in pregnancyWhat to do when someone becomes pregnant on a newer ART regimen that is not yet recommended by the guidelinesAnnette Haberl, MDPhysicianHead of HIV and WomenHIVCENTER FrankfurtDepartment of Infectious DiseaseHospital of the Johann Wolfgang Goethe UniversityFrankfurt, GermanyWilliam R. Short, MD, MPH, AAHIVSAssociate Professor of MedicineDivision of Infectious DiseasesDepartment of MedicinePerelman School of Medicine at the University of PennsylvaniaPhiladelphia, PennsylvaniaLink to full program:https://bit.ly/3HPu4Lk

In this episode, Paul E. Sax, MD, discusses long-acting (LA) injectables for HIV treatment, including: Guidance on the use of LA cabotegravir (CAB) + rilpivirine (RPV)Risk factors for virologic failure of LA CAB + RPVThe ATLAS-2M studyCombined clinical trials of LA CAB + RPVPractical considerations for LA CAB + RPVImplementation of LA CAB + RPV Switching to LA CAB + RPV without an oral lead-in, including a discussion of the FLAIR extension studySupporting candidates for LA antiretroviral therapy (ART)Discussion of an implementation study of LA CAB + RPV in patients with challenges to oral ART adherence in San FranciscoFuture LA ART The investigational LA HIV capsid inhibitor lenacapavir (LEN)LEN resistance from the CAPELLA and CALIBRATE studiesLEN injection-site reactions in the CAPELLA and CALIBRATE studiesPresenter: Paul E. Sax, MDClinical DirectorHIV Program and Division of Infectious DiseasesBrigham and Women's HospitalProfessor of MedicineHarvard Medical SchoolBoston, MassachusettsLink to full program:https://bit.ly/3VIsDTgFollow along with the slides at:http://bit.ly/3Gh9AKG

When you should you say no to a customer? Wes Michael shares a wealth of thought this subject and why you should think about it first. A market research industry veteran of over 40 years, Wes earned his MBA from the University of Chicago Booth School of Business and a BA in English from the University of Pennsylvania. In 2013, Wes launched Rare Patient Voice based on a novel approach to building a market research panel, one that enables patients and caregivers to share their voices with the researchers and companies developing products to improve patients' lives. He structured the company on the core values of being a good resource for patients, a good partner to clients, a good employer to staff, and a good citizen in our community. Since then, Wes has seen the company grow, expanding from the US to Canada, the United Kingdom, Spain, Italy, France, and Germany, completing thousands of projects, and providing customized service to hundreds of clients. He hopes that RPV's work can help the lives of patients and caregivers who are able to participate in our studies, and of those who come after. Hobbies: Walking his dogs, piano, history, exercise Pets: Ace (mix of Beagle and Brittany) and Stanley the Chocolate Lab Likes: Hearing from patients who have enjoyed taking part in a study Dislikes: When no one qualifies for a study Fun Facts: Wes spent a year in Edinburgh, Scotland and ran cross country with the Hare & Hounds MAIN TAKEAWAYS: “You need to have a folder somewhere… where you say: IDEAS (...) Don't loose track of these things” “Deadlines are important. We work towards deadlines. But you can negotiate, you can talk to them, let them know...” “You've got to look at what's the fair amount. Somebody doesn't deserve all of your time.”

In this episode, Tristan J. Barber, MA, MD, FRCP, and Darcy Wooten, MD, discuss switching ART with virologic suppression, including:Switching with prior or unknown resistanceData on switching to BIC/FTC/TAF with a preexisting M184V/I mutation from a pooled analysis of 6 phase III studiesThe impact of baseline resistance on outcomes following a switch to BIC/FTC/TAF in Black PWH from the BRAAVE 2020 studyA post hoc analysis of the SALSA study of DTG/3TC outcomes at Week 48 by baseline resistanceData from the SOLAR 3D study on switching to DTG/3TC from a 3- or 4-drug ART regimen with a history of M184VA retrospective analysis of switching to DTG/3TC with archived M184V/I from the French Dat'AIDS CohortSwitching to long-acting ARTGuidance on candidates for LA CAB + RPVData on risk factors for virologic failure with LA CAB + RPVConsidering an ART switch after weight gainData on weight gain after ART initiation by ARV class and drugMean change in weight by sex at Week 96 in the ADVANCE studyDHHS guideline recommendations regarding weight gain with ARTTristan J. Barber, MA, MD, FRCPHonorary Associate ProfessorInstitute for Global HealthUniversity College LondonConsultant in HIV MedicineIan Charleson Day CentreRoyal Free HospitalLondon, United Kingdom  Darcy Wooten, MDAssociate Professor of MedicineDivision of Infectious Diseases and Global Public HealthDepartment of MedicineUniversity of California, San DiegoSan Diego, California

It's operation Askari, and 61 Mech's has fulfilled the first part of the plan, driving FAPLA out of Quiteve and now were approaching Cahama, which is 96 kilometers north west of Xangongo. This was going to be a tough nut to crack. FAPLAs second Brigade was ensconced in strongly fortified positions to the north and south of the town. The defenders had become used to SADF and SA Air Force attacks, if you remember during Operation Protea the Air Force had hammered radar installations at Cahama and the Recces spent a lot of time around the little town. So after years of battering, defences had been beefed up, bunkers were deeper, heavier weapons abounded. Busy in the air through most of November and December 1983 was the SA Air Force's Garrha Remote Piloted Vehicle, or drone, and it had discovered the location of enemy SA8 missile systems. The photographs were blurry, but the location was clear. They were in positions around the town. Brigadier Joop Joubert who commanded all SADF forces during Askari expected these defenders to wilt as the pressure rose through December and into January 1984 – he just needed time to do – and time was not on his side. However, in what turned out to be a jaw-dropping miscommunication, the planners forgot to inform the Air Force about Combat Team Delta Foxtrot, which was about 45km south west of Caiundo on the western bank of the Cubango River. That was about 130km east of the main target of Cuvelai, and even in a Puma or a Mirage, that's a long way to go to offer support. On the 23rd of December and about 2 kilometers west of Cahama, the SA Air Force drone was damaged by shrapnel from an SA-8 ground to air missile. The operators managed to keep the RPV in the air and it headed back to Xangongo where it landed safely.

It's operation Askari, and 61 Mech's has fulfilled the first part of the plan, driving FAPLA out of Quiteve and now were approaching Cahama, which is 96 kilometers north west of Xangongo. This was going to be a tough nut to crack. FAPLAs second Brigade was ensconced in strongly fortified positions to the north and south of the town. The defenders had become used to SADF and SA Air Force attacks, if you remember during Operation Protea the Air Force had hammered radar installations at Cahama and the Recces spent a lot of time around the little town. So after years of battering, defences had been beefed up, bunkers were deeper, heavier weapons abounded. Busy in the air through most of November and December 1983 was the SA Air Force's Garrha Remote Piloted Vehicle, or drone, and it had discovered the location of enemy SA8 missile systems. The photographs were blurry, but the location was clear. They were in positions around the town. Brigadier Joop Joubert who commanded all SADF forces during Askari expected these defenders to wilt as the pressure rose through December and into January 1984 – he just needed time to do – and time was not on his side. However, in what turned out to be a jaw-dropping miscommunication, the planners forgot to inform the Air Force about Combat Team Delta Foxtrot, which was about 45km south west of Caiundo on the western bank of the Cubango River. That was about 130km east of the main target of Cuvelai, and even in a Puma or a Mirage, that's a long way to go to offer support. On the 23rd of December and about 2 kilometers west of Cahama, the SA Air Force drone was damaged by shrapnel from an SA-8 ground to air missile. The operators managed to keep the RPV in the air and it headed back to Xangongo where it landed safely.

By November 1983 the SADF was prepping for the significant operation called Askari, and the Air Force was playing its part. The original plan was for the op to start on the 9th November but political negotiations had led to a postponement to the 9th December. Meanwhile, the SA Air Force had sent up their remotely piloted vehicle or RPV– in Xangongo under Major Jinx Botes. The aim was to monitor the Cahama area initially as part of a sub-Askari operation called Fox . The RPV was code-named Gharra and was trying to detect the location of SA-8 missile systems sent to the South by the Angolans – courtesy of the Russians. It proved a rather hit and miss process, these were early days in the use of what we now know as drones. Time to take a closer look at Operation Askari which was broken into four phases. First, the Special Forces would recce deep into Angola, then the SA Air Force would bomb the Typhoon and Volcano base near Lubango. Phase 2 would see offensive reconnaissance around Cahama, Mulondo and Cuvelai and the SADF estimated this could take as long as two months, starting at least a week after phase 1 had kicked off. The main aim was to cut off SWAPO and FAPLAs communication and logistics lines, and to demoralize the SWAPO sections leading to their withdrawal north. However, the SADF missed a crucial bit of information when assessing their options in phase two – they presumed both FAPLA and SWAPO morale was low, but that was not the case. It was higher than it had been for years. SWAPO's PLAN armed wing had been withdrawn into Angola for retraining. And These fighters were briefed about the new heavy weapons sent by the Russian sponsors - including T54/55 tanks – as well as the new missile systems. Demoralizing them this time was not going to be as easy as in 1981. Phase three which was to begin after the invasion was to reinforce the gaps supposedly created by Askari west of the Cunene River, through Quiteve, Mupa, Vinticette and then to Ionde. The last phase was to reinforce the empty bases once SWAPO and FAPLA left, and thus stop this year's incursions into SWA.

By November 1983 the SADF was prepping for the significant operation called Askari, and the Air Force was playing its part. The original plan was for the op to start on the 9th November but political negotiations had led to a postponement to the 9th December. Meanwhile, the SA Air Force had sent up their remotely piloted vehicle or RPV– in Xangongo under Major Jinx Botes. The aim was to monitor the Cahama area initially as part of a sub-Askari operation called Fox . The RPV was code-named Gharra and was trying to detect the location of SA-8 missile systems sent to the South by the Angolans – courtesy of the Russians. It proved a rather hit and miss process, these were early days in the use of what we now know as drones. Time to take a closer look at Operation Askari which was broken into four phases. First, the Special Forces would recce deep into Angola, then the SA Air Force would bomb the Typhoon and Volcano base near Lubango. Phase 2 would see offensive reconnaissance around Cahama, Mulondo and Cuvelai and the SADF estimated this could take as long as two months, starting at least a week after phase 1 had kicked off. The main aim was to cut off SWAPO and FAPLAs communication and logistics lines, and to demoralize the SWAPO sections leading to their withdrawal north. However, the SADF missed a crucial bit of information when assessing their options in phase two – they presumed both FAPLA and SWAPO morale was low, but that was not the case. It was higher than it had been for years. SWAPO's PLAN armed wing had been withdrawn into Angola for retraining. And These fighters were briefed about the new heavy weapons sent by the Russian sponsors - including T54/55 tanks – as well as the new missile systems. Demoralizing them this time was not going to be as easy as in 1981. Phase three which was to begin after the invasion was to reinforce the gaps supposedly created by Askari west of the Cunene River, through Quiteve, Mupa, Vinticette and then to Ionde. The last phase was to reinforce the empty bases once SWAPO and FAPLA left, and thus stop this year's incursions into SWA.

We're baaaaaack!Step back in the ring with RPV for Wrestlemania X8!It's icon vs icon, brevity vs elder abuse, Tim Curry vs SPACE!

Medical researchers have FINALLY realized something that we in the chronic illness space have known for a while - that the true experts are not necessarily those who have studied a condition but are in fact those of us who live with a condition 24 hours a day, seven days a week, 365 days a year. Due to this realization, researchers now want to include our voices (as well as those of our family caregivers) in their studies. And we are getting paid for our time and input. Because it can be difficult to connect with patients and caregivers, there are organizations that exist to join the dots. One of these is Rare Patient Voice (RPV), and my guest today is Mel Havert, the Patient Outreach Manager for RPV. Mel's role is based around connecting with patients and caregivers, and inviting them to the RPV panel so that they can assist with research opportunities and make their voices heard.Listen in to find out how you can be involved, improve medical research, and get paid for your time and experience!In this episode:What is Rare Patient Voice and what does it do?How patients can join and how the RPV process worksThe key question - how much patients can be paid?!What RPV does (and doesn't do) with your personal data How patients can sign up to RPV via the PGP affiliate linkFull notes and resources at https://patientsgettingpaid.com/blog/paid-research-patient-experience